Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Immunogen Inc (IMGN)

Pharmaceutical Preparations

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

830 WINTER ST
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/31/1989

Market Cap

8,725,621,690

Shares Outstanding

279,350,000

Weighted SO

279,354,016

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

MDGL --.--%

ICPT --.--%

TGTX --.--%

TERN --.--%

HEPA --.--%

VKTX --.--%

AXSM --.--%

MCRB --.--%

MREO --.--%

Beta

1.1710

Last Div

0.0000

Range

3.61-31.25

Chg

0.0050

Avg Vol

8287745

Mkt Cap

8725621690

Exch

NASDAQ

Country

US

Phone

781 895 0600

DCF Diff

42.8921

DCF

-11.6621

Div Yield

0.0000

P/S

30.3380

EV Multiple

-119.3572

P/FV

15.9953

Div Yield %

0.0000

P/E

-122.9285

PEG

-1.2293

Payout

0.0000

Current Ratio

5.4673

Quick Ratio

5.4673

Cash Ratio

4.4968

DSO

165.8588

DIO

518.7985

Op Cycle

684.6573

DPO

2346.4421

CCC

-1661.7848

Gross Margin

0.9866

Op Margin

-0.2788

Pretax Margin

-0.2524

Net Margin

-0.2541

Eff Tax Rate

-0.0066

ROA

-0.0889

ROE

-0.2197

ROCE

-0.1166

NI/EBT

1.0066

EBT/EBIT

0.9053

EBIT/Rev

-0.2788

Debt Ratio

0.0575

D/E

0.0842

LT Debt/Cap

0.1138

Total Debt/Cap

0.0776

Int Coverage

-20.2641

CF/Debt

-4.1872

Equity Multi

1.4639

Rec Turnover

2.2007

Pay Turnover

0.1556

Inv Turnover

0.7035

FA Turnover

16.6955

Asset Turnover

0.3499

OCF/Share

-0.6881

FCF/Share

-0.6947

Cash/Share

2.1055

OCF/Sales

-0.6880

FCF/OCF

1.0095

CF Coverage

-4.1872

ST Coverage

7.9624

CapEx Coverage

-104.7586

Div&CapEx Cov

-104.7586

P/BV

15.9953

P/B

15.9953

P/S

30.3380

P/E

-122.9285

P/FCF

-43.6766

P/OCF

-45.3935

P/CF

-45.3935

PEG

-1.2293

P/S

30.3380

EV Multiple

-119.3572

P/FV

15.9953

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 07, 07:33 Is AbbVie Stock a Buy Now? The Motley Fool Jan 07, 07:33 Is AbbVie Stock a Buy Now? MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 04:52 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target The Motley Fool Dec 26, 08:30 AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why The Motley Fool Dec 12, 10:15 AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors The Motley Fool Dec 10, 05:51 AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool Dec 10, 05:51 AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool Dec 08, 05:38 AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? Benzinga Dec 07, 15:19 AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals The Motley Fool Dec 07, 06:05 Is AbbVie Stock a Buy Now? Seeking Alpha Dec 07, 02:28 The Magnificent 7 Aren't So Magnificent Right Now, Buy Seeking Alpha Dec 07, 02:28 The Magnificent 7 Aren't So Magnificent Right Now, Buy Benzinga Dec 04, 10:44 ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note Seeking Alpha Dec 02, 02:24 AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time

Revenue Product Segmentation